Which medications in the drug class Antiplatelet Agents are used in the treatment of Wellens Syndrome?

Updated: Jan 25, 2018
  • Author: Benjamin B Mattingly, MD; Chief Editor: Erik D Schraga, MD  more...
  • Print

Antiplatelet Agents

Antiplatelet agents inhibit platelet aggregation.

Abciximab (ReoPro)

Abciximab is a chimeric human-murine monoclonal antibody approved for use in elective, urgent, or emergency percutaneous coronary intervention (PCI). It binds to the receptor with high affinity and reduces platelet aggregation by 80% for as long as 48 hours after infusion.

Clopidogrel (Plavix)

Clopidogrel selectively inhibits adenosine diphosphate (ADP) binding to platelet receptors and subsequent ADP-mediated activation of the glycoprotein (GP) IIb/IIIa complex, thereby inhibiting platelet aggregation.

Clopidogrel may have a positive influence on several hemorrhagic parameters and may exert protection against atherosclerosis not only through inhibition of platelet function but also through changes in the hemorrhagic profile. It has been shown to lower the rates of cardiovascular death, MI, and stroke in patients with acute coronary syndrome (ie, unstable angina and non-Q-wave MI).

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!